Emerging Prognostic Biomarkers in Non Small Cell Lung Cancer Patients:Impact of Treatment with Nimesulide (COX-2 Inhibitor) Combined with Chemotherapy
- *Corresponding Author:
- Dr. Aliae AR Mohamed Hussein
Associate Professor of Pulmonology
Assiut University Hospitals
Assiut , Egypt
E-mail: [email protected]
Received date: November 14, 2011; Accepted date: Dececmber 16, 2011; Published date: Dececmber 18, 2011
Citation: Abdel Ghany SM, El Melegy NT, Mohamed-Hussein AAR, Hana RS (2011) Emerging Prognostic Biomarkers in Non Small Cell Lung Cancer Patients: Impact of Treatment with Nimesulide (COX-2 Inhibitor) Combined with Chemotherapy. J Pulmonar Respirat Med S5:003. doi:10.4172/2161-105X.S5-003
Copyright: © 2011 Abdel Ghany SM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To date, the treatment outcome of non small cell lung cancer (NSCLC) is still not satisfactory and new treatment options are urgently needed. The present study was designed to: 1) evaluate the effects of the antiangiogenic drug; nimesulide (NSAID, a COX-2 inhibitor) combined with chemotherapy on NSCLC treatment progress, 2) Evaluate the role of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), as prognostic indicators in NSCLC, 3) Correlate the above parameters levels with the clinicopathological status of the patients during the therapy. The study included 30 NSCLC. The patients were divided to: group I, included 17 patients received chemotherapy alone and group II included 13 patients received the same chemotherapy with Nimesulide and 10 as controls. Serum and biopsies were taken for all subjects on admission and 3 weeks after the completion of treatment. Results: serum and tissue levels of VEGF and bFGF, were significantly higher in NSCLC patients and decreased significantly after treatment specially in group II compared to group I. The serum and tissue levels of the studied parameters decreased significantly in the responders as compared to resistant cases. The response rate after combined therapy was 69% versus 53% after chemotherapy alone. In conclusion, Nimesulide appears to boost the efficacy of the traditional chemotherapy as its co-administration showed encouraging effects on improving and normalization of the proangiogenic parameters levels and in turn the vascular supply of tumors. This may have good impact on the patient outcome, prolongation of their survival rate and prognosis.